Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (DE:J7Z)
FRANKFURT:J7Z
Jazz Pharmaceuticals (J7Z) Stock Price & Analysis
1 Followers
J7Z Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€99.06 - €134.35
Previous Close€104.6
Volume0.00
Average Volume (3M)22.00
Market Cap
€6.42B
Enterprise Value€10.56B
Total Cash (Recent Filing)$1.34B
Total Debt (Recent Filing)$5.78B
Price to Earnings (P/E)N/A
Beta0.29
Next Earnings
Aug 06, 2024EPS Estimate
€4.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding63,039,618
10 Day Avg. Volume4
30 Day Avg. Volume22
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-1.98
Price to Sales (P/S)1.80
Price to Cash Flow (P/CF)10.20
P/FCF Ratio8.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.79
Enterprise Value/Gross Profit2.51
Enterprise Value/Ebitda18.01
Forecast
1Y Price Target
€173.77Price Target Upside71.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Jazz Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial ValuationJazz is trading at an all-time low 5.5x NTM consensus P/E, an extreme discount believed to be unjustified.
Pipeline DevelopmentPotential upside from the pipeline, including zanidatamab for HER2+ cancers, which could get initial accelerated approval this year.
Product PerformanceSolid growth in Xywav patient numbers suggests strong brand performance and minimal impact from competition.
Bears Say
Financial PerformanceJazz kicked off with sloppy 1Q results—one of its largest top and bottom line misses.
Profitability ConcernsJazz reported a lower than expected non-GAAP EPS of $5.02 compared to the consensus of $5.18, which could raise concerns about profitability going forward.
Tax Rate Impact2024 tax rate will increase from 6.7% to 10-13% due to a higher global minimum tax rate.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
6.22% Other Institutional Investors
93.78% Public Companies and
Individual Investors
J7Z FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was €99.06 and its highest was €134.35 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Currently, no data Available
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 94 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on May 01, 2024. The company reported €2.501 earnings per share for the quarter, missing the consensus estimate of €3.9 by -€1.399.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is €4.36.
How many shares outstanding does Jazz Pharmaceuticals have?
Currently, no data Available
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of €2.501 in its last earnings report, missing expectations of €3.9. Following the earnings report the stock price went down -9.162%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 156M.
---
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€173.77 (71.63% Upside)
€173.77 (71.63% Upside)
Blogger Sentiment
Bullish
DE:J7Z Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $997.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.24%
12-Months-Change
Fundamentals
Return on Equity
9.41%
Trailing 12-Months
Asset Growth
2.53%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
J7Z Company Deck
---
J7Z Earnings Call
Q1 2024
0:00 / 0:00
---
J7Z Stock 12 Months Forecast
Average Price Target
€173.77
▲(71.63% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Ionis Pharmaceuticals
―
Sangamo Biosciences
―
Vertex Pharmaceuticals
―
Neurocrine
―
Best Analysts Covering J7Z
1 Year
1 Year Success Rate
13/26 ratings generated profit
1 Year Average Return
+2.48%
reiterated a buy rating 3 days ago
Copying Ken Cacciatore's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.48% per trade.
---